Pharmaceuticals company Alivus Life Sciences announced Q1FY26 results Revenue from operations for Q1FY26 reached Rs 6,018 million, a growth of 2.2% YoY. EBITDA was at Rs 1,813 million, a growth of 9.9% YoY. EBITDA margins were at 30.1%, up 210 bps YoY. PAT for the quarter stood at Rs 1,215 million and PAT margins were at 20.2%. During Q1FY26, the company generated a strong free cash flow of Rs 1,000 million leading to Cash and Cash Equivalents (including short term investments) of Rs 6,604 million as of June 30, 2025. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said: "Our performance this quarter was primarily driven by strong growth in the Non-GPL business, which expanded by 14.5% YoY. Key regions including India (Ex-GPL), Europe, ROW, LATAM, and Japan were major contributors to this growth. We remain confident of achieving high single-digit revenue growth in FY26, with stronger momentum expected in the second half. Margins are projected to remain healthy in the 28–30% range. Our ongoing investments in capacity building and pipeline enrichment form the foundation of our future growth, and we believe these efforts, supported by an increasingly favourable market environment, will help unlock further value." Tushar Mistry, CFO, Alivus Life Sciences, said: "Q1FY26 witnessed robust revenues of Rs 602 crore, while consistently maintaining our gross margin at ~55% and EBITDA margin around ~30%, well within our guided range. This financial discipline, coupled with a healthy free cash flow of Rs 100 crore during the quarter, strengthens our debt-free balance sheet and positions us well to achieve the high single-digit growth we anticipate for the full year." Result PDF
Pharmaceuticals company Alivus Life Sciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations for Q4FY25 reached Rs 6,496 million, a growth of 21.1% YoY and 1.2% QoQ. For Q4FY25, EBITDA was at Rs 2,085 million, a growth of 44.2% YoY and 3.8% QoQ. EBITDA margins were at 32.1%, up 520 bps YoY and up 80 bps QoQ. PAT for the quarter stood at Rs 1,419 million and PAT margins were at 21.8%. FY25 Financial Highlights: For FY25, revenue from operations was Rs 23,869 million, a growth of 4.5% YoY. EBITDA for FY25 was at Rs 7,172 million while EBITDA margins stood at 30.0% as compared to 30.1% in FY24 despite the absence of PLI benefit in the current year. For FY25, the company recorded PAT of Rs 4,857 million with PAT margins of 20.3%. During FY25, the company generated a strong free cash flow of Rs 2,328 million leading to Cash and Cash Equivalents (including short term investments) of Rs 5,487 million as of 31 March 2025. Commenting on the company’s performance Yasir Rawjee, MD & CEO, Alivus Life Sciences said, "FY25 was our first full year under the Nirma ownership. Our overall performance has remained consistent with past years, with sustained margins, despite facing external challenges, most notably the loss in PLI revenue. The road ahead has significant opportunities for which we have begun working in earnest via capacity investments and the integration of newer technologies into R&D; and manufacturing operations One of the most encouraging outcomes this year was our ability to maintain EBITDA margins at 30%, even in the absence of PLI benefits and amid market headwinds. This reflects the strength of our diversified portfolio and our continued focus on operational efficiency. Our full-year sales grew by 7.1%, normalizing for the PLI benefit last year and backed by healthy contributions from both GPL and Non-GPL segments. As we move into FY26, we remain committed to delivering sustainable growth with stable margins, while continuing to invest in our core growth drivers, expanding our product pipeline, and scaling our operations to create long-term value." Tushar Mistry, CFO, Alivus Life Sciences said, "We delivered strong revenue growth of 21.1% in Q4FY25, with 520 bps improvement in EBITDA margins at 32.1%. We concluded the year on a positive note, with full-year revenue growth of 7.1% normalised for PLI benefits, which has been in line with our earlier guidance. For FY25, both gross margins and EBITDA margins remained stable at ~55% and ~30% respectively, supported by a favourable product mix and cost discipline. Notably, we maintained EBITDA margins of 30% without PLI scheme benefits, a strong validation of our operational resilience. Alivus Life Sciences has generated healthy cash flows of Rs 233 Crore during the year, which supports our growth initiatives while enabling us to maintain a debt-free balance sheet." Result PDF
Pharmaceuticals company Alivus Life Sciences announced 9MFY25 & Q3FY25 results Revenue from operations for Q3FY25 reached Rs 6,418 million, a growth of 12.0% YoY and 26.6% QoQ. For 9MFY25, revenue from operations was Rs 17,373 million. For Q3FY25, EBITDA was at Rs 2,008 million, a growth of 15.2% YoY and 40.5% QoQ. EBITDA margins were at 31.3%, up 90 bps YoY and 310 bps QoQ. EBITDA for 9MFY25 was at Rs 5,086 million while EBITDA margins stood at 29.3%. PAT for the quarter stood at Rs 1,370 million and PAT margins were at 21.3%. For 9MFY25, the company recorded PAT of Rs 3,438 million with PAT margins of 19.8%. During 9MFY25, the company generated a strong free cash flow of Rs 1,838 million leading to Cash and Cash Equivalents (including short term investments) of Rs 4,993 million as of 31 December 2024. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said: “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. Our quest for high-quality, innovative solutions and scalability continues, in order to build a sustainable business over the long term.” Tushar Mistry, CFO, Alivus Life Sciences, said: “Our emphasis on achieving quality growth has delivered encouraging outcomes with highest ever quarterly revenue at Rs 6,418 million. This translated to steady gross margins at ~56%, while our EBITDA grew by 15.2% YoY, underscoring our ability to cater a diversified product range while maintaining stringent cost efficiency." Result PDF
Pharmaceuticals company Glenmark Life Sciences announced Q2FY25 results For H1FY25, GLS registered a revenue from operations of Rs 10,955 million, a de-growth of 6.7% YoY. For Q2FY25, revenue from operations was at Rs 5,069 million. EBITDA for H1FY25 was at Rs 3,079 million, a de-growth of 16.2% YoY while EBITDA margins stood at 28.1%. For Q2FY25, EBITDA was at Rs 1,429 million and EBITDA margins were at 28.2%, up 20 bps QoQ. PAT for H1FY25 was at Rs 2,068 million whereas for the quarter it stood at Rs 953 million. During H1FY25, company generated strong free cash flow of Rs 1,340 million, leading to Cash and Cash Equivalents of Rs 4,461 million as of 30 September, 2024. Yasir Rawjee, MD & CEO, Glenmark Life Sciences said: “The temporary closure of Ankleshwar facility has resulted in delayed servicing of orders, impacting the quarter revenue across geographies. However, the loss of production has substantially been recovered and we expect H2FY25 to be better than the earlier estimates. A key highlight is that our product mix has led to better gross margins i.e. above 55%. Looking ahead, we expect a strong second half of the fiscal year, supported by our solid order book. While overall growth for FY25 is projected to be in high single digits, we are confident in maintaining stable margins throughout the year.” Tushar Mistry, CFO, Glenmark Life Sciences said: “I am pleased to share that despite the temporary setback, our gross margins improved both year-on-year and sequentially, returning to approximately 55.6%, while EBITDA margins remained steady at around 28.2%. GLS generated a solid cash flow of Rs 134 crores during H1FY25, enabling continued growth and allowing us to maintain a debt-free balance sheet." Result PDF
Conference Call with Glenmark Life Sciences Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Glenmark Life Sciences Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Glenmark Life Sciences announced Q1FY25 results: Financial Highlights: For Q1FY25, GLS registered a revenue from operations of Rs 5,886 million, recording a growth of 9.7% QoQ and 1.8% YoY. EBITDA for Q1FY25 was at Rs 1,650 million, a growth of 14.1% QoQ and EBITDA margins were at 28%, up 110 bps QoQ. PAT for Q1FY25 was at Rs 1,115 million, a growth of 13.9% QoQ. During Q1FY25, company generated strong free cash flow of Rs 1,213 million, leading to Cash and Cash Equivalents of Rs 4,263 million as of 30 June, 2024. Business Highlights: Generic business in Q1 FY25 grew by 10.5% QoQ and 6.2% YoY to Rs 5,354 million whereas CDMO business grew by 20.2% QoQ to Rs 425 million. DMF / CEPs filing continue across major markets, taking the total cumulative filings to 532 as on 30 June 2024 In Q1FY25, Addition of 5 new products to the development grid, of which 3 products are High potent API (HP API) / Oncology class of drugs and 2 are synthetic small molecules. The HP API portfolio now extends to 20 products with an addressable market of USD 40 billion (Source: IQVIA, MAT Mar’24); 4 products are validated, and 4 products are in advanced stages of development. Commenting on the company’s performance Yasir Rawjee, MD & CEO, Glenmark Life Sciences said, “We are pleased to report broad-based revenue growth for the quarter, where, as anticipated, growth has picked up sequentially. Our Generic API business experienced a robust 10.5% QoQ and 6.2% YoY growth. YoY growth was led by Europe, LATAM and RoW. The GPL business saw a significant recovery this quarter. With the key drivers of our business - GPL, Non-GPL and CDMO performing well, we anticipate delivering steady growth with stable margins throughout FY25.” Tushar Mistry, CFO, Glenmark Life Sciences said, “Q1FY25 has been marked by a recovery in growth. While gross margins were impacted by the discontinuation of the PLI benefit to GLS as well as product mix, employee costs have normalized, leading to stable EBITDA margins of 28% for Q1FY25. We are optimistic about maintaining the growth momentum for the rest of the year. GLS generated strong cash flow of Rs. 121 crores during the quarter, further strengthening our debt-free balance sheet.” Result PDF